Search Results - yves+pommier

7 Results

Sort By:

Oxynitidine Derivatives Useful as Inhibitors of Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treating Cancer

Summary: The National Cancer Institute (NCI) is actively seeking potential licensees and/or co-development research collaboration partners interested in advancing oxynitidine derivatives as novel inhibitors of topoisomerase IB (TOP1) and tyrosyl-DNA phosphodiesterase 1 (TDP1) for cancer treatment. These TOPI and TDP1 inhibitors, when administered...

Published: 4/24/2026 | Updated: 9/13/2024 | Inventor(s): Yves Pommier, Lin-kun An, Keli Agama, Evgeny Kiselev, Azhar Ravji

Keywords(s): Benzophenanthridine Derivatives, Benzophenanthridinone, Camptothecin, Dihydrobenzophenanthridine, IRINOTECAN, Oxynitidine, Pommier, Tdp1, TOP1, Topoisomerase 1B, Topotecan, Tyrosyl-DNA Phosphodiesterase 1

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Application > Therapeutics

Enhanced Cancer Chemotherapy Using the Bioactive Peptide Recifin And Its Analogues

Summary: NCI seeks research co-development partners and/or licensees for the development of recifin and its analogues as new chemosensitizing agents in adjunct therapies with topotecan, irinotecan and related chemotherapeutic agents. Description of Technology: Topoisomerase enzymes play an important role in cancer progression by controlling changes...

Published: 4/24/2026 | Updated: 8/2/2023 | Inventor(s): Barry O'Keefe, Lauren Krumpe, Johan Rosengren, Ingrid Schroeder, Alan Bermingham, Christophe Marchand, Kirk Gustafson, Brice Wilson, Yves Pommier

Keywords(s): CANCER, Chemosensitizing Agents, CHEMOTHERAPY, Cyclic Peptide, Irinotecan TOP1, O’Keefe, Recifin, Tdp1, Topoisomerase 1 inhibitors, Topotecan, Tyrosyl-DNA Phosphodiesterase 1 Inhibitors

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Collaboration Sought > Licensing, Application > Therapeutics

Novel Small Molecule Inhibitors of Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treatment of Solid Tumors

Summary: The NCI seeks proposals from parties interested in licensing and/or co-development for commercializing the use of TDP1 inhibitors as part of a potent and selective anti-cancer combination therapy. Description of Technology: Topoisomerase 1 (TOP1) is an essential enzyme that plays a critical role in DNA transcription and replication. TOP1...

Published: 4/23/2026 | Updated: 8/2/2023 | Inventor(s): Xue Zhao, George Lountos, Evgeny Kiselev, David Waugh, Yves Pommier, Terrence Burke

Keywords(s): Burke, CANCER, solid tumor, Tdp1, TOP1, Topoisomerase 1, Tyrosyl-DNA Phosphodiesterase 1, Zhao

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology

Synergistic Use of Exo VII Inhibitors And Quinolone Antibiotics For Treating Bacterial Infection

Summary: The NCI seeks co-development partners or licensees to further develop the novel ExoVII inhibitor(s) as antibiotic adjuvants for enhancing the efficacy of quinolone antibiotics, particularly in quinolone-resistant bacterial strains. Description of Technology: Topoisomerase poisons, such as quinolone antibiotics, are widely used as anticancer...

Published: 4/24/2026 | Updated: 8/2/2023 | Inventor(s): Yves Pommier, Shar-yin Huang, Brianna Mitchell

Keywords(s): Antibacterial, Antibiotic Adjuvants, Antibiotic Resistance, DNA gyrase, Exonuclease VII, ExoVII, Infection, Pommier, Quinolone, TOPO IV, Topoisomerase Poisons

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, Application > Therapeutics

Small Molecule Inhibitors of Drug Resistant Forms of HIV-1 Integrase

Abstract: Integrase strand transfer inhibitors (“INSTIs”) are currently in use as a component of prophylactic antiretroviral therapy for preventing HIV-1 infection from progressing to AIDS. Three INSTIs are approved by the FDA for inclusion in antiretroviral regiments: raltegravir (RAL), elvitegravir (EVG) and dolutegravir (DTG). Clinicians have already...

Published: 4/22/2025 | Updated: 8/2/2023 | Inventor(s): Xue Zhao, Terrence Burke, Yves Pommier, Stephen Hughes, Mathieu Metifiot, Stephen Smith, Barry Johnson, Christophe Marchand

Keywords(s): dolutegravir, drug resistant HIV, elvitegravir, HIV therapy, Integrase, raltegravir, strand transfer

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing

Use of Acetalax for Treatment of Triple Negative Breast Cancer

Summary: NCI seeks research co-development and/or potential licensees for a potential novel treatment for triple-negative breast cancer (TNBC) with acetalax (oxyphenisatin acetate). Description of Technology: Triple negative (progesterone receptor (PR)-, estrogen receptor (ER)-, human epidermal growth receptor 2 (HER2)-) breast cancer (TNBC) is an...

Published: 4/24/2026 | Updated: 8/2/2023 | Inventor(s): William Reinhold, Matthew Garnett, Vinodh Rajapakse, Yves Pommier, Augustin Luna

Keywords(s): Acetalax, Oxyphenisatin Acetate, Pommier, TNBC, Triple Negative Breast Cancer, Uterine Cancer

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology

Novel Furoquinolinediones as Inhibitors of TDP2 and Their Potential Use to Treat Cancer

Summary: The National Cancer Institute (NCI) seeks licensees for a family of novel furoquinolinedione derivatives that inhibit tyrosyl-DNA phosphodiesterase 2 (TDP2) as cancer therapeutics. Description of Technology: Tyrosyl-DNA phosphodiesterase 2 (TDP2) is an enzyme that plays a critical role in repairing nucleic acid lesions, namely by repairing...

Published: 1/12/2026 | Updated: 8/2/2023 | Inventor(s): Christophe Marchand, Lin-kun An, Yves Pommier

Keywords(s): CANCER, Combination Therapies, Pommier, therapeutic, Topoisomerase 2 (TOP2), Tyrosyl-DNA Phosphodiesterase 2 (TDP) Inhibitors

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics